The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist.

The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist.

Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the controversy regarding the pharmacological action...

Full description

Bibliographic Details
Main Authors:	Catherine E Erickson, Rukhsana Gul, Christopher P Blessing, Jenny Nguyen, Tammy Liu, Lakshmi Pulakat, Murat Bastepe, Edwin K Jackson, Bradley T Andresen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3748024?pdf=render

Similar Items

ACKR4 Recruits GRK3 Prior to β-Arrestins but Can Scavenge Chemokines in the Absence of β-Arrestins
by: Christoph Matti, et al.
Published: (2020-04-01)

Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells.
by: Abuzar Mahmood, et al.
Published: (2015-01-01)

Isoprenaline and salbutamol inhibit pyroptosis and promote mitochondrial biogenesis in arthritic chondrocytes by downregulating β-arrestin and GRK2
by: Iqra Ajmal, et al.
Published: (2022-09-01)

The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol
by: T. D. Giles
Published: (2011-12-01)

GRK specificity and Gβγ dependency determines the potential of a GPCR for arrestin-biased agonism
by: Edda S. F. Matthees, et al.
Published: (2024-07-01)

Regulation of Constitutive GPR3 Signaling and Surface Localization by GRK2 and β-arrestin-2 Overexpression in HEK293 Cells.
by: Katie M Lowther, et al.
Published: (2013-01-01)

Treatment with β-blocker nebivolol ameliorates oxidative stress and endothelial dysfunction in tenofovir-induced nephrotoxicity in rats
by: Mariana Moura Nascimento, et al.
Published: (2022-08-01)

β-Arrestin2-biased Drd2 agonist UNC9995 alleviates astrocyte inflammatory injury via interaction between β-arrestin2 and STAT3 in mouse model of depression
by: Yang Liu, et al.
Published: (2022-10-01)

GRK6 palmitoylation dictates triple-negative breast cancer metastasis via recruiting the β-Arrestin 2/MAPKs/NF-κB signaling axis
by: Wen-Ke Wang, et al.
Published: (2024-12-01)

Antiarrhythmic Properties of Beta Blockers: Focus on Nebivolol
by: Bülent Görenek, et al.
Published: (2024-06-01)

Editorial: Repurposing β-blockers for non-cardiovascular diseases
by: Ayaz Shahid, et al.
Published: (2024-02-01)

NEBIVOLOL SAFETY AS CARDIOSELECTIVE Β-BLOCKER IN COMPLEX THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE ACCOMPANIED BY CHRONIC OBSTRUCTIVE BRONCHITIS
by: Zh. G. Simonova, et al.
Published: (2003-10-01)

β-Arrestin1 and β-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4
by: Gianluca D’Agostino, et al.
Published: (2020-09-01)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

ArreSTick motif controls β-arrestin-binding stability and extends phosphorylation-dependent β-arrestin interactions to non-receptor proteins
by: András Dávid Tóth, et al.
Published: (2024-05-01)

Illuminating β-arrestin conformational dynamics by fluorine NMR
by: Bin Xia
Published: (2024-05-01)

NEBIVOLOL: A THIRD GENERATION BETA BLOCKER AS ANTIHYPERTENSION AGENT
by: Ni Putu Wirantari, et al.
Published: (2013-07-01)

The modern treatment of cardiovascular diseases with b-blockers - focus on the nebivolol.
by: Anna Grigor'evna Evdokimova, et al.
Published: (2009-12-01)

Distinct and shared roles of β-arrestin-1 and β-arrestin-2 on the regulation of C3a receptor signaling in human mast cells.
by: Arpana Vibhuti, et al.
Published: (2011-05-01)

Comparison of the Usefulness of SPE Cartridges for the Determination of β-Blockers and β-Agonists (Basic Drugs) in Environmental Aqueous Samples
by: Magda Caban, et al.
Published: (2015-01-01)

Improved Split TEV GPCR β-arrestin-2 Recruitment Assays via Systematic Analysis of Signal Peptide and β-arrestin Binding Motif Variants
by: Yuxin Wu, et al.
Published: (2022-12-01)

β-arrestin-1 and β-arrestin-2 Restrain MRGPRX2-Triggered Degranulation and ERK1/2 Activation in Human Skin Mast Cells
by: Zhao Wang, et al.
Published: (2022-07-01)

Grk
by: Skok Petar
Published: (1954-01-01)

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases
by: Teresa R. Kee, et al.
Published: (2024-01-01)

β-Blockers in COPD
by: Iman Galal
Published: (2014-04-01)

Agonist-independent interactions between β-arrestins and mutant vasopressin type ii receptors associated with nephrogenic syndrome of inappropriate antidiuresis
by: Kocan, M, et al.
Published: (2009)

Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation
by: Justyna Piekielna-Ciesielska, et al.
Published: (2020-12-01)

Cell-Specific Protective Signaling Induced by the Novel AT2R-Agonist NP-6A4 on Human Endothelial and Smooth Muscle Cells
by: Ryan Toedebusch, et al.
Published: (2018-08-01)

The β2-adrenergic biased agonist nebivolol inhibits the development of Th17 and the response of memory Th17 cells in an NF-κB-dependent manner
by: Mehri Hajiaghayi, et al.
Published: (2024-10-01)

Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization.
by: Dipannita Basu, et al.
Published: (2013-01-01)

β-arrestin2 Mediates the Arginine Vasopressin-Induced Expression of IL-1β in Murine Hearts
by: Na Yao, et al.
Published: (2023-01-01)

β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility
by: Jihee Kim, et al.
Published: (2018-12-01)

SNX9 family mediates βarrestin-independent GPCR endocytosis
by: Valeria L. Robleto, et al.
Published: (2024-11-01)

Research progress in the role of β-arrestin 1 in the regulation of inflammatory response
by: YI Wenjing, et al.
Published: (2024-12-01)

The incidence of candidate binding sites for β-arrestin in Drosophila neuropeptide GPCRs
by: Paul H. Taghert
Published: (2022-01-01)

β-arrestin regulates estradiol membrane-initiated signaling in hypothalamic neurons.
by: Angela M Wong, et al.
Published: (2015-01-01)

Functional differences in the mu opioid receptor SNP 118A>G are dependent on receptor splice‐variant and agonist‐specific recruitment of β‐arrestin
by: Casey Patrick, et al.
Published: (2024-08-01)

Evaluation of the Intracellular Signaling Activities of κ-Opioid Receptor Agonists, Nalfurafine Analogs; Focusing on the Selectivity of G-Protein- and β-Arrestin-Mediated Pathways
by: Masahiro Yamaguchi, et al.
Published: (2022-10-01)

β2-Adrenoceptor involved in smoking-induced airway mucus hypersecretion through β-arrestin-dependent signaling.
by: Yujiao Zhou, et al.
Published: (2014-01-01)